Cross-Border Impact Ventures (CBIV) has recently announced the successful closing of its Women’s and Children’s Health Technology Fund, raising over $90 million in investor commitments. The fund is dedicated to investing in technology companies that address the health needs of women, children, and adolescents, and also aims to enhance the resilience of health systems.
Based in North America and Europe, CBIV targets investments in medical device, diagnostic, and digital health companies with global growth and high return prospects. The fund primarily focuses on healthcare software companies with annual revenues between $1M and $10M and companies developing technologies that require regulatory approval, with at least one product approved by CE Mark or FDA. In addition, CBIV employs a gender lens in its investment strategy and collaborates with portfolio companies to improve diversity and ensure broader access to their products.
Among the notable limited partners (LPs) who contributed to the fund are KfW, investing on behalf of Germany’s Federal Ministry for Economic Cooperation and Development, M&G’s Catalyst, Wire Group, and several family offices and foundations including Ceniarth, Skoll Foundation, The Nathan Cummings Foundation, Fondation du Grand Montréal, Guy’s & St Thomas’ Foundation, and the McConnell Foundation.
These LPs join CBIV’s earlier investors, which include the Children’s Investment Fund Foundation, Global Health Investment Corporation, Hamilton Community Foundation, Grand Challenges Canada, J&J Impact Ventures, Rally Total Impact Fund, and The RockCreek Group. The fund is also supported by a guarantee from the Swedish International Development Cooperation Agency (SIDA).
CBIV has already made five investments since its launch in December 2021. The portfolio includes companies like Pendulum, Daye, mOm Incubators, Sonio, and OncoLens, each contributing innovative solutions in the field of healthcare technology, ranging from AI-driven health infrastructure and gynecological care platforms to portable incubators for neonatal care, AI-enabled software for pregnancy complications, and digital health platforms for oncology care management.
“Our current portfolio has the potential to make a difference in the lives of millions of women, children, and adolescents in North America and Europe, in addition to targeting underserved populations in emerging markets,” said Annie Thériault, Managing Partner at CBIV. “Our fundraising success proves that there is a large pool of investors that believes they can earn market returns while achieving ambitious impact targets with their dollars.”
“Our unique expertise in investing in MedTech and HealthTech companies focused on women’s, children’s, and adolescents’ health along with our impact approach is sought after by pipeline companies. We bring in industry and clinical experts from our international network to unlock growth and impact,” said Donna Parr, Managing Partner at CBIV. “We are building a portfolio of investments that we know is of interest to strategic acquirers.”
The successful closure of CBIV’s fund signifies an important milestone in advancing health technology solutions that cater to the specific needs of women, children, and adolescents, while also demonstrating the viability of achieving market returns alongside impactful health outcomes.
